statins and glp-1 Disrupt Metabolism By Lowering Despite overriding cardiovascular benefit, statins

proposed that intermediaries of the ghrelin axis, such as GHS-R1b, could potentially serve as a clinical target for gastric disorders (111)

Finally, the receptor pool that IGF-I uses for driving hypertrophy may provide another potential avenue for therapeutic strategies

Diseases of the Central Nervous System That May Benefit from the Treatment with GLP-1RA Diabetes mellitus is one of the main risk factors for the development of cognitive dysfunction

Although an increase in heart-rate per se is not a major problem for most people, it is salient in the case of GLP1R, GIPR or GR agonists since the target patient population of these agonist are obese patients, who likely already suffer from cardiovascular complications